Modelling and simulation can streamline decision making in drug safety testing.

Computational cardiac electrophysiology is a mature technology with a long heritage.

There are many challenges and opportunities in using in silico techniques in future.

We discuss how models can be used at different stages of drug discovery.

CiPA will combine screening platforms, human cell assays and in silico predictions.